ALID.US Allied Corp
- Market cap
- USD 57.7K
- P/E
- -
- P/B
- 52.50x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Nov 2024.
Is ALID.US undervalued?
Graham numberThe Graham number of Allied Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Allied Corp fundamental analysis
No fundamental analysis for Allied Corp yet.
Allied Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Allied Corp
Allied Corp., a cannabis company, engages in the development, manufacture, and marketing of hemp derived cannabis products in the United States. It operates in two segments, Allied Colombia and Allied Corp. The company offers hemp-based CBD natural health products, as well as cannabis related products, including beauty and skincare products, and food and beverages. It also develops ALID 10 and ALID 11 for the treatment of post-traumatic stress disorder and related mental hea…
Full company profileAllied Corp financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 1 quarter up to Nov 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Allied Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.5K | 166K | 72.1K | 96.2K | 111K |
| Gross Profit | 9.00K | 0.00 | 0.00 | 0.00 | -90.5K | -625K | 74.1K | -1.46M | -323K | 54.4K |
| Operating Income | -2.06K | -20.3K | -19.3K | -23.1K | -3.51M | -7.60M | -14.3M | -10.3M | -2.84M | -2.06M |
| EBITDA | -2.06K | -20.3K | -19.3K | -23.1K | -3.04M | -7.05M | -14.2M | -6.69M | -2.99M | - |
| Net Income | -2.06K | -20.3K | -19.3K | -23.1K | -6.76M | -12.2M | -16.8M | -10.7M | -3.98M | -3.12M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.08 | -0.15 | -0.18 | -0.11 | -0.04 | -0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 7.16K | 151.00 | 756.00 | 103.00 | 7.10M | 4.63M | 5.79M | 2.06M | 2.11M | 1.95M |
| Total Liabilities | 4.35K | 17.6K | 37.4K | 59.9K | 3.40M | 5.60M | 7.07M | 8.95M | 9.66M | 9.59M |
| Shareholders' Equity | 2.81K | -17.4K | -36.7K | -59.8K | 3.70M | -971K | -1.28M | -6.88M | -7.55M | -7.64M |
| Cash & Short-term Investments | 0.00 | 0.00 | 756.00 | 103.00 | 94.0K | 420K | 96.0K | 210K | 359K | 195K |
| Total Debt | - | - | - | - | 2.00M | 3.73M | 5.08M | 5.86M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.50K | -14.1K | -21.1K | -12.6K | -3.16M | -3.96M | -4.28M | -1.96M | -2.00M | -2.04M |
| Capital Expenditure | 0.00 | 0.00 | 2.00M | 2.00M | 112K | 224K | 1.21M | 87.8K | 9.89K | 150K |
| Free Cash Flow | -4.50K | -14.1K | -21.1K | -12.6K | -3.27M | -4.18M | -5.49M | -2.04M | -2.01M | -2.19M |
| Ratios | ||||||||||
| ROE | -73.3% | - | - | - | -182.6% | - | - | - | - | - |
| ROA | -28.8% | -13,411.3% | -2,546.7% | -22,435.0% | -95.2% | -262.4% | -289.7% | -517.3% | -188.0% | -160.0% |
| Net Profit Margin | -22.9% | - | - | - | - | -97,133.6% | -10,129.0% | -14,807.6% | -4,134.1% | -2,820.1% |
| Debt to Equity | - | - | - | - | 0.54x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Allied Corp dividends
Allied Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 6.666:1 on Aug 7, 2019.
Who owns Allied Corp
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 115M
- Free float 84.4M
Allied Corp company profile
- Company name
- Allied Corp
- Ticker
- ALID.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- August
- Address
- 200-460 Doyle Ave, Kelowna, BC, Canada, V1Y OC2
- Phone
- 877-255-4337
- Website
- allied.health
About Allied Corp
Allied Corp., a cannabis company, engages in the development, manufacture, and marketing of hemp derived cannabis products in the United States. It operates in two segments, Allied Colombia and Allied Corp. The company offers hemp-based CBD natural health products, as well as cannabis related products, including beauty and skincare products, and food and beverages. It also develops ALID 10 and ALID 11 for the treatment of post-traumatic stress disorder and related mental health conditions through the targeted function of the 5-HT2 receptor and physiological pathways. The company is headquartered in Kelowna, Canada.
Allied Corp management
4- Mr. Michael MosesChief Executive Officer
- Dr. Radka Milanova Ph.D.Chief Scientific Director
- Mr. Tim LevyHead of Cultivation
- Mr. Mark MosesChief of Staff